CN1569015A - Application of saponins in the preparing process of coxsackie virus resisting medicine - Google Patents
Application of saponins in the preparing process of coxsackie virus resisting medicine Download PDFInfo
- Publication number
- CN1569015A CN1569015A CN 03141639 CN03141639A CN1569015A CN 1569015 A CN1569015 A CN 1569015A CN 03141639 CN03141639 CN 03141639 CN 03141639 A CN03141639 A CN 03141639A CN 1569015 A CN1569015 A CN 1569015A
- Authority
- CN
- China
- Prior art keywords
- virus
- medicine
- timosaponin
- iii
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the medical use of Timosaponin a-III, wherein the Timosaponin a-III is extracted and isolated from the Chinese medicinal herb anemarrhena rhizome as the active constituent with the structural formula disclosed in the specification, medical experiment has proved that the Timosaponin a-III can suppress Coxsackie Group B Virus and treat virus cardiomyopathy.
Description
Technical field
The present invention relates to a kind of from the Chinese medicine Rhizoma Anemarrhenae saponin active ingredient of extraction separation, can significantly suppress Coxsackie virus B (Coxsackie Group B Virus) and treatment viral myocarditis through the pharmacological testing proof, more specifically refer to the effective ingredient 1-timosaponin A-1 of extraction separation from the Chinese medicine Rhizoma Anemarrhenae
m, it can be used in the medicine of the anti-Coxsackie virus of preparation.
Background technology
Coxsackie virus can cause multiple disease, mainly causes viral myocarditis as Coxsackie virus B.Viral myocarditis system is a kind of common clinical of major lesions with myocardial cell degeneration necrosis, inflammatory cell infiltration, and is occurred frequently in child and teenager, the serious harm human health.
At present, the main method of doctor trained in Western medicine clinical treatment viral myocarditis is to use common antiviral agents, immunosuppressant, interferon and myocardial cell nutrient etc., but curative effect is unsatisfactory.
In recent years, Chinese medicine demonstrates very big advantage in the clinical treatment of viral myocarditis.At present have only indivedual kinds at the Chinese patent medicine of viral myocarditis clinically, and be crude extract preparation (as stilbene winter chin or cheek heart oral liquid), mostly be the doctor greatly from the prescription decoction of intending, urgent need is developed targetedly, effective ingredient and pharmacological action are clear, dosage form advanced person, taking convenience, Chinese medicine preparation stable and controllable for quality.
Chinese medicine Rhizoma Anemarrhenae clearing away heat-fire promotes the production of body fluid and moisturizes, and mainly has effects such as antibiotic, analgesic, blood sugar lowering, but does not see the effective site of its treatment viral myocarditis and the report of effective ingredient.1-timosaponin A-1
IIIThe pharmacological action of monomer component does not appear in the newspapers yet.
Summary of the invention
The objective of the invention is to overcome the weak point that conventional Chinese medicine exists, from Chinese medicine, seek a class formation and determine, have antivirus action and in anti-Coxsackie virus of preparation and prophylactic treatment viral myocarditis medicine, use.Adopt chemical method from the Chinese medicine Rhizoma Anemarrhenae, to isolate effective ingredient---1-timosaponin A-1
III,, this chemical compound is used in the medicine of anti-Coxsackie virus of preparation and treatment viral myocarditis through pharmacological testing.
The present invention adopts the Chinese medicine rhizoma ane marrhenae through alcohol reflux 3 times, and filtrate decompression is reclaimed, and makes Rhizoma Anemarrhenae extractum, with the low amounts of water dissolving, use the water saturation n-butanol extraction again, n-butanol layer is mixed silicagel column on the sample with methanol, with n-butyl alcohol-chloroform (1: 1) eluting, separate obtaining the pure compound 1-timosaponin A-1
IIIStructural formula is as follows:
Its molecular formula is C
39H
64O
13, molecular weight is 740, chemistry Sarsasapogenin by name-3-O-β-D-glucopyranosyl (1 → 2)-β-D-galactopyranoside.
1-timosaponin A-1
IIIExtraction process is with reference to " chemical composition of Chinese materia medica extraction separation handbook ", and Yang Yun edits, China Traditional Chinese Medicine Publishing House, front page in 1998.
The present invention adopts said method to extract the 1-timosaponin A-1 that obtains
IIIAt first carry out the conventional test of pesticide effectiveness.
In vivo test:
The Balb/c mice is divided into 3 groups at random.
1, normal control group: do not give 1-timosaponin A-1
III, virus inoculation is not only given the equivalent distilled water;
2, virus control group: abdominal cavity inoculation 0.1mlCVB
3Virus liquid (TCID
50=10
-7.5, 10
5Doubly dilution).
3, administration group: the same method inoculation CVB
3Virus liquid is irritated the stomach 1-timosaponin A-1 on the same day
III(1-timosaponin A-1
IIIBe dissolved in a small amount of dimethyl sulfoxine, the reuse normal saline is diluted to 8.35mg/ml) 0.15mmol/kgd, successive administration 7 days was observed 15 days;
Observe diet, hair color and the active situation etc. of mice, and the statistics mortality rate.
Experimental result shows, the virus group is dead 50%, and medicine of the present invention can will be by coxsackie B
3The mortality rate of the mice with viral myocarditis that virus causes significantly is reduced to 7.1%.
The present invention adopts the dosage grouping of above-mentioned test, and successive administration 7 days was observed 15 days, then mice was dissected, and scale mice body weight before dissection weighs its cardiac weight again after the dissection, calculate its cardiac index then.Computational methods are:
Cardiac index=heart weight/body weight
After animal was by viral infection, food ration reduced, and body weight reduces, and therefore heart expands, and fibrosis takes place and becomes heavy, so can weigh the lesion degree of heart with cardiac index, cardiac index is big more, and heart change is serious more.
The result shows that medicine of the present invention can significantly reduce by coxsackie B
3The cardiac index of the mice with viral myocarditis that virus causes.
Mouse heart is done pathological section after putting and fixing in the formalin.Examine under a microscope inflammatory cell infiltration and myocardium cell necrosis situation then.Each specimen is observed 5 visuals field, and each visual field pathological changes 0-25% is designated as 1, and 25%-50% is designated as 2, and 50%-75% is designated as 3, and 75%-100% is designated as 4, then is designated as 0 as no pathological changes.
Experimental result shows that medicine of the present invention can effectively improve by coxsackie B
3The lesion degree of the mouse heart that virus causes.
In vitro tests:
Get 1-3 days neonatal rat of SD rat, do myocardial cell former be commissioned to train foster.Add viral liquid behind the 24h and hatch 1h, discard viral liquid, medicine dissolution of the present invention in normal saline, is suitably diluted the back with culture fluid and adds the Tissue Culture Plate cultivation.With Tissue Culture Plate multigelation 3 times, virion is fully discharged behind the 72h, measure the virus titer in each hole.
The result shows that medicine of the present invention can effectively reduce coxsackie B
3The virus titer of virus infected cell has the remarkable vitro antiviral effect.
Annotate: test method is with reference to " modern pharmacology experimental technique " (volume two, P
1425, Zhang Juntian chief editor, combined publication society of China Concord Medical Science University of Beijing Medical University, version in 1998).
The specific embodiment
The present invention is further elaborated below in conjunction with specific embodiment, but it is not had any restriction.
Embodiment 1: medicine of the present invention is to the influence test (in the body) of mice with viral myocarditis mortality rate
Get 34 of Balb/c mices, be divided into 3 groups at random.
The normal control group: 6, do not give medicine of the present invention, also virus inoculation is not only given the equivalent distilled water.
The virus control group: 14, every abdominal cavity inoculation 0.1mlCVB
3Virus liquid (TCID
50=10
-7.5, 10
5Doubly dilution).
The administration group: 14, the same method inoculation CVB
3Virus liquid is irritated stomach by 0.15mmol/kgd on the same day and is given medicine of the present invention, and successive administration 7 days was observed to the 15th day.
The situations such as the mental status, diet, hair color and death of animal during the observed and recorded administration (raising).
The result: medicine of the present invention can significantly reduce by coxsackie B
3The mortality rate of the mice with viral myocarditis that virus causes sees Table 1.
Table 1 medicine of the present invention is to the influence of mice with viral myocarditis mortality rate
| Group | Number of animals (only) | Dead routine number | Mortality rate |
| Normal control papova matched group administration group | 6 14 14 | 0 7 1 | 0 50％ 7.1％** |
Annotate: adopt X 2 test, the administration group is organized relatively * * P＜0.01 with virus
Embodiment 2: medicine of the present invention is to the influence test (in the body) of mice with viral myocarditis cardiac index
Balb/c mice group and dosage are with embodiment 1.Successive administration 7 days is observed the 15th day, and all mices are all dissected.The body weight of scale mice before dissection weighs its cardiac weight again after the dissection.
Cardiac index=heart weight/body weight
After animal was by viral infection, food ration reduced, and body weight reduces, and therefore heart expands, fibrosis takes place and becomes weight, so can weigh the lesion degree of heart with cardiac index, cardiac index is big more, and heart change is serious more.
The result: medicine of the present invention can significantly reduce by coxsackie B
3The cardiac index of the mice with viral myocarditis that virus causes sees Table 2.
Table 2 medicine of the present invention is to the influence of mice with viral myocarditis cardiac index
Group cardiac index (* 10
-3)
Normal control group 5.80 ± 0.60
Virus control group 8.23 ± 1.33
Administration group 6.20 ± 0.57
*
Annotate: the administration group compares with the virus group:
*P＜0.05,
*P＜0.01
Embodiment 3: medicine of the present invention is to the influence test (in the body) of mice with viral myocarditis pathological section
Balb/c mice group and dosage are with embodiment 1.Administration 7 days is observed the 15th day, after the dissection mouse heart is put in the formalin fixingly, does pathological section.Examine under a microscope the downright bad situation of myocardium inflammatory cell infiltration and cardiac muscle fiber.Each specimen is observed 5 visuals field, and each visual field pathological changes 0-25% is designated as 1, and 25%-50% is designated as 2, and 50%-75% is designated as 3, and 75%-100% is designated as 4, then is designated as 0 as no pathological changes.
Experimental result shows that medicine of the present invention can effectively improve by coxsackie B
3The lesion degree of the mouse heart that virus causes.
Table 2 medicine of the present invention is to the influence of mice with viral myocarditis heart pathological section
| Group | 0 | + | ++ | +++ | ++++ | Average |
| Virus group administration group | 1 4 | 2 5 | 1 0 | 0 1 | 3 3 | 2.2 1.46* |
Annotate: employing nonparametric statistics check, the administration group compares * P＜0.05 with the virus group
Embodiment 4: medicine of the present invention is to the influence (external) of virus infected cell virus titer
Get 1-3 days neonatal rat of SD rat freshman, do myocardial cell former be commissioned to train foster, with 24 well culture plates at CO
2Cultivate in the incubator.Discard culture fluid behind the 24h, the viral liquid that adds dilution in 1: 60 is hatched 1h, discards viral liquid, and medicine of the present invention is dissolved in (10mg/ml) in the normal saline, and the reuse culture fluid adds drug solution dilution in 1: 200 Tissue Culture Plate and cultivates.Behind the 72h, pathological development is to suitable degree, with Tissue Culture Plate multigelation 3 times, virion fully discharged, with hep-2 raji cell assay Raji virus titer.
The gained result represents with negative logarithm, is called neutralization index, can characterize virus virulence.Neutralization index is big more, and the expression virus virulence is strong more.According in " the new drug pharmacodynamic study guideline " of the issue of national Bureau of Drugs Supervision described in " antiviral property myocarditis medicine " chapter, for antiviral drugs, virus virulence reduces by 1 index, and promptly neutralization index reduces by 1, even if effectively.
The result shows that medicine of the present invention can effectively reduce coxsackie B
3The virus titer of virus infected cell has the remarkable vitro antiviral effect.
Table 3 medicine of the present invention is to the influence of virus infected cell virus titer
| Group | Neutralization index |
| Virus control group medicine cultivation group | 4.75 2.13 * |
Annotate: according to " new drug pharmacodynamic study guideline ",
*For statistical significance is arranged.
Claims (3)
1. 1-timosaponin A-1 that structural formula is following
IIIThe purposes of chemical compound, it has anti-Coxsackie virus B effect.
2. 1-timosaponin A-1 according to claim 1
IIIThe purposes of chemical compound is characterized in that using in the medicine of the disease that the preparation prophylactic treatment is caused by Coxsackie virus B.
3. 1-timosaponin A-1 according to claim 1
IIIThe purposes of chemical compound is characterized in that using in preparation prevention, the treatment viral myocarditis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03141639XA CN1310650C (en) | 2003-07-16 | 2003-07-16 | Application of saponins in the preparing process of coxsackie virus resisting medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB03141639XA CN1310650C (en) | 2003-07-16 | 2003-07-16 | Application of saponins in the preparing process of coxsackie virus resisting medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1569015A true CN1569015A (en) | 2005-01-26 |
| CN1310650C CN1310650C (en) | 2007-04-18 |
Family
ID=34470999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03141639XA Expired - Fee Related CN1310650C (en) | 2003-07-16 | 2003-07-16 | Application of saponins in the preparing process of coxsackie virus resisting medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1310650C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110623965A (en) * | 2019-10-24 | 2019-12-31 | 南昌大学第二附属医院 | Timosaponin composition and application thereof in treating viral myocarditis |
| CN110882266A (en) * | 2019-10-24 | 2020-03-17 | 南昌大学第二附属医院 | Timosaponin composition and application thereof in treating viral myocarditis |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101307090B (en) * | 2007-05-16 | 2011-04-13 | 中国科学院上海药物研究所 | Method for preparing timosaponin BIII and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411733A (en) * | 1992-04-27 | 1995-05-02 | Hozumi; Toyoharu | Antiviral agent containing crude drug |
| WO2002011669A2 (en) * | 2000-08-07 | 2002-02-14 | Antigenics, Llc | Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof |
| CN1177592C (en) * | 2002-07-31 | 2004-12-01 | 首都儿科研究所 | Myocarditis treating medicine |
-
2003
- 2003-07-16 CN CNB03141639XA patent/CN1310650C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110623965A (en) * | 2019-10-24 | 2019-12-31 | 南昌大学第二附属医院 | Timosaponin composition and application thereof in treating viral myocarditis |
| CN110882266A (en) * | 2019-10-24 | 2020-03-17 | 南昌大学第二附属医院 | Timosaponin composition and application thereof in treating viral myocarditis |
| CN110623965B (en) * | 2019-10-24 | 2022-09-16 | 上海市第五人民医院 | Timosaponin composition and application thereof in treating viral myocarditis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1310650C (en) | 2007-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872105A (en) | Application of holly and extractive in preparing medication for anti virus | |
| CN1472220A (en) | Triterpene extracts from achyranthes roots and their use in medicine against osteoporosis | |
| CN1813711A (en) | Use of isoflavone compound | |
| CN1310650C (en) | Application of saponins in the preparing process of coxsackie virus resisting medicine | |
| CN1887323A (en) | Chinese medicine composition and its prepn process and quality control method | |
| CN1965853A (en) | Application of gentiopicroside in preparation of antiviral medicament | |
| CN1799564A (en) | Application of valeriana wallichii and its extract in preparation of medicine for treating anxiety neurosis | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN1201737C (en) | Application of cepharanthine in preparing medicine for resisting SARS virus | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| CN1265797C (en) | Application of timosaponin A3 for preparing medicine for treating No.2 type diabetes mellitus | |
| CN1839855A (en) | Ginsenoside F1 medicinal uses | |
| CN101040891A (en) | Preparation method and application of tripterygium hypoglaucum alkaloids | |
| CN1537852A (en) | Anti coxsackie viruse action of quinolixiding kind alkaloid | |
| CN1398861A (en) | Prepn and application in preparing medicine of Fraxinus general coumarin | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN1833674A (en) | Wart gel and prepn. method | |
| CN1273150C (en) | Medicine for treating depression and its preparing method | |
| CN1895554A (en) | Chinese herb for inhibiting tumor and its preparation | |
| CN103655755A (en) | Anti-influenza drug and preparation method thereof | |
| CN1535698A (en) | Chinese medicine compound preparation and its preparation process | |
| CN104758282B (en) | Berberine is for preparing the purposes of the medicine of viral myocarditis disease caused by treatment Coxsackie B virus 3 | |
| CN106581101A (en) | Application of radix bupleuri volatile oil in preparation of medicine for treating neurodegenerative disease | |
| CN1259043C (en) | Application of salvia acid in pharmacy | |
| CN102973716A (en) | Rehmanniae oral solution for relaxing bowel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070418 Termination date: 20120716 |